10-Q: Virios Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Virios Therapeutics reported a net loss of $1.3 million for the first quarter of 2024 and is actively seeking partnerships and funding to advance its clinical programs.

Summary

• Virios Therapeutics, a development-stage biotechnology company, reported a net loss of $1.3 million for the first quarter of 2024, compared to a net loss of $1.5 million for the same period in 2023.
• The company's research and development expenses decreased to $0.3 million from $0.5 million year-over-year, primarily due to reduced spending on toxicology studies and regulatory consulting.
• General and administrative expenses also decreased to $1.0 million from $1.1 million, mainly due to lower insurance costs.
• As of March 31, 2024, Virios had $2.4 million in cash and an accumulated deficit of $62.8 million.
• The company is exploring partnership opportunities to advance its lead product candidate, IMC-1, into Phase 3 development for fibromyalgia.
• Positive data from an exploratory study of IMC-2 in Long-COVID has led to a second investigator-initiated study, with results expected in the summer of 2024.
• Virios needs to raise additional capital within the next three to five months to continue operations and advance its clinical programs.
• The company's stock is currently at risk of being delisted from Nasdaq due to not meeting the minimum bid price requirement.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the company's financial challenges, including the need for additional funding and the risk of delisting, despite some positive clinical data and strategic initiatives.

Positives

• The company has received positive feedback from the FDA regarding its proposed Phase 3 program for IMC-1.
• An exploratory study of IMC-2 in Long-COVID showed statistically significant improvements in fatigue, pain, and autonomic dysfunction.
• The company has secured a global patent for IMC-2 covering antiviral treatment of Long-COVID.
• All employees and directors have agreed to a 10% compensation reduction in exchange for future stock options.

Negatives

• The company incurred a net loss of $1.3 million in the first quarter of 2024.
• The company's cash balance of $2.4 million is not sufficient to fund operations for the next 12 months.
• The company needs to raise additional capital within the next three to five months to continue operations.
• The company's stock is at risk of being delisted from Nasdaq due to not meeting the minimum bid price requirement.
• The company has an accumulated deficit of $62.8 million.

Risks

• The company's ability to continue as a going concern is in doubt due to insufficient cash reserves.
• There is no assurance that the company will be able to secure additional financing on acceptable terms.
• Failure to secure necessary financing could delay product development and clinical trial plans.
• The company's stock is at risk of being delisted from Nasdaq.
• The company is subject to risks associated with development-stage biotechnology companies, including substantial expenditures for research and development and no current revenue generation.

Future Outlook

The company plans to raise additional capital to complete clinical development of its product candidates and is exploring partnership opportunities. They anticipate results from the second Long-COVID study in the summer of 2024 and are planning a potential IND submission for IMC-2.

Management Comments

• Management is actively exploring opportunities for IMC-2 for Long-COVID and complementary opportunities that will build shareholder value through strategic partnerships, collaborations or other transactions.
• Management has emphasized their commitment to long-term success and value creation by agreeing to a 10% salary compensation reduction in exchange for future vesting stock options.

Industry Context

The company is focused on developing novel antiviral therapies for diseases associated with herpesvirus activation, a growing area of interest in the medical community. The company's approach of combining antiviral and anti-inflammatory agents is unique and may offer a new treatment paradigm for conditions like fibromyalgia and Long-COVID.

Comparison to Industry Standards

• The company's cash burn rate is typical for a development-stage biotech company, but the current cash balance is insufficient to fund operations for the next 12 months, which is a concern.
• The company's reliance on external funding is common in the biotech industry, but the current market conditions make securing financing more challenging.
• The company's focus on novel combination therapies is a differentiating factor compared to other companies developing single-agent treatments.
• The company's progress in Long-COVID is notable, as there are limited effective treatments currently available for this condition.

Related Party Transactions

• The company uses Gendreau Consulting, LLC, a consulting firm, for drug development and clinical trial activities. Gendreaus managing member is the company's Chief Medical Officer.

Stakeholder Impact

• Shareholders are impacted by the company's financial challenges and the risk of delisting.
• Employees are impacted by the 10% salary reduction in exchange for future stock options.
• Patients with fibromyalgia and Long-COVID may benefit from the company's clinical programs if successful.
• The company's suppliers and creditors are impacted by the company's financial situation.

Next Steps

• The company plans to submit a potential investigational new drug (IND) application to formally access IMC-2 as a treatment for the symptoms associated with Long-COVID.
• The company will continue prototype development of IMC-2 to be used for the Phase 2 Long-COVID study.
• The company will continue funding the grant to the BHC for ongoing execution of their double-blinded, placebo controlled investigator-sponsored study of Long-COVID with the combination of Val/Cel.
• The company will present a plan to regain compliance to the Nasdaq hearings panel, including a discussion of the events that the company believes will enable it to regain compliance, including the anticipated receipt of data from the study of IMC-2 for the treatment of Long-COVID being conducted by the Bateman Horne Center as well as a commitment to effect a reverse stock split, if necessary.

Key Dates

Keywords

Virios Therapeutics, biotechnology, fibromyalgia, Long-COVID, IMC-1, IMC-2, clinical trials, antiviral, herpesvirus, funding, Nasdaq, delisting